Make sure you get the green bottle

Image of a climber swinging from a mouth of a cave

DISCOVER ALPHAGAN® P 0.1%

What is glaucoma?

Glaucoma is a disease that can damage the eye’s optic nerve. It usually develops when fluid pressure inside the eye (or eye pressure) slowly rises, causing high eye pressure, or ocular hypertension. Glaucoma is a leading cause of blindness.

What is ALPHAGAN® P 0.1%?

ALPHAGAN® P 0.1% is a prescription eye drop approved to lower eye pressure (IOP) in patients with open-angle glaucoma or high eye pressure (ocular hypertension).

Why ALPHAGAN® P 0.1%?

ALPHAGAN® P 0.1% offers reduced drug exposure with the lowest dose of active ingredient among all Allergan brimonidine brands.

Be Sure You Get The
Green Bottle

Alpha Green Bottle
  • Be sure to get ALPHAGAN® P 0.1% in the green bottle from your pharmacy. ALPHAGAN® P 0.1%:
    • Contains a lower concentration of the active ingredient with the same effectiveness as compared with the original ALPHAGAN® 0.2%
    • Is preserved with Purite®, which breaks down into natural tear components in the eye
    • Has no FDA-approved generic equivalent

How is ALPHAGAN® P 0.1% thought to work?

Although the exact way ALPHAGAN® P 0.1% may work is unknown, it is thought to reduce eye pressure in 2 ways.

INDICATIONS AND USAGE

ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% or 0.15% is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Neonates and Infants (under the age of 2 years): ALPHAGAN® P is contraindicated in neonates and infants (under the age of 2 years).

Hypersensitivity Reactions: ALPHAGAN® P is contraindicated in patients who have exhibited a hypersensitivity reaction to any component of this medication in the past.

WARNINGS AND PRECAUTIONS

Potentiation of Vascular Insufficiency: ALPHAGAN® P may potentiate syndromes associated with vascular insufficiency. ALPHAGAN® P should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, or thromboangiitis obliterans.

Severe Cardiovascular Disease: Although brimonidine tartrate ophthalmic solution had minimal effect on the blood pressure of patients in clinical studies, caution should be exercised in treating patients with severe cardiovascular disease.

Contamination of Topical Ophthalmic Products After Use: There have been reports of bacterial keratitis associated with the use of multiple-dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface.

DRUG INTERACTIONS

Antihypertensives/Cardiac Glycosides: Because ALPHAGAN® P may reduce blood pressure, caution in using drugs such as antihypertensives and/or cardiac glycosides with ALPHAGAN® P is advised.

CNS Depressants: Although specific drug interaction studies have not been conducted with ALPHAGAN® P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.

Tricyclic Antidepressants: Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with ALPHAGAN® P in humans can lead to resulting interference with the IOP-lowering effect. Caution is advised in patients taking tricyclic antidepressants, which can affect the metabolism and uptake of circulating amines.

Monoamine Oxidase Inhibitors: Monoamine oxidase (MAO) inhibitors may theoretically interfere with the metabolism of brimonidine and potentially result in an increased systemic side effect such as hypotension. Caution is advised in patients taking MAO inhibitors, which can affect the metabolism and uptake of circulating amines.

ADVERSE REACTIONS

Adverse reactions occurring in approximately 10% to 20% of the subjects receiving brimonidine ophthalmic solution (0.1% to 0.2%) included: allergic conjunctivitis, conjunctival hyperemia, and eye pruritus. Adverse reactions occurring in approximately 5% to 9% included: burning sensation, conjunctival folliculosis, hypertension, ocular allergic reaction, oral dryness, and visual disturbance

Please click here for full ALPHAGAN® P 0.1% Prescribing Information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1 (800)-FDA-1088.